Investing.comCodex · 实盘不做把握 4/10不做原因:证据不足
北京时间·🕒 发布 18:48:41·⟳ 抓取 18:49:19 +38s·⚡ 决策 08-31 18:51:10 +1m51s·57.0 天前
礼来拟以最高28.75亿美元现金收购Merida Biosciences以补强自身免疫管线
事件本身对礼来长期管线偏正面，但标的是超大市值药企、资产处于Phase 1且对价相对收入基数有限；同时缺少可执行报价和必要先例量化，不能给出正期望交易单。
📄 原文Investing.com↗ 原文
Lilly to acquire Merida Biosciences for up to $2.875 billion
Oil rises 3% as U.S. strikes on Iran revive Hormuz supply disruption concerns INDIANAPOLIS and CAMBRIDGE, Mass. - Eli L…
不做 Eli Lilly and Company（LLY.US）
早期管线收购对超大市值礼来的短线业绩弹性不足，且缺少真实报价和先例量化，不形成可执行正期望。
不做 Merida Biosciences, Inc.（N/A）
被收购方为私人公司，未识别到可直接交易证券。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
礼来以最高28.75亿美元收购Merida，新增自身免疫和过敏疾病早期生物药平台，方向偏利好；但MER511仍在Phase 1，短期收入贡献不可量化。礼来近期已连续进行多笔数十亿美元级BD交易，Q2收入指引基数为850亿至870亿美元，本次对价约为年收入指引中点的3.3%，更多是长期管线布局而非短线业绩重估催化，因此不做。
消息传播链
- Investing.com转述礼来宣布收购Merida Biosciences，最高对价28.75亿美元；未能打开页面复核发布时间以外的原始网页元数据。
关键理由
- 本次收购补强礼来自身免疫疾病早期管线，MER511针对Graves病和甲状腺眼病的致病自身抗体机制具有差异化。
- 量级上，最高28.75亿美元对价约为礼来2026年收入指引中点860亿美元的3.3%，但资产仍处Phase 1，短期收入和利润增量基本不可见。
主要风险
- 交易仍需监管批准和成交条件，且里程碑付款、会计处理和研发费用影响尚未披露。
- 礼来近期已有多笔BD和IPR&D支出，单笔早期资产收购容易被市场视为常规管线补强而非新增强催化。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-05 · 影响 weakens
礼来此前已披露多笔BD和IPR&D费用，削弱单笔早期管线收购的短线预期差。
检索:Lilly 2026 acquisitions IPR&D charges revenue guidance 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足促使本次从潜在LONG降为AVOID。
方向:未取得可用event_study先例，不能用历史样本支持短线做多。
涨幅量级:没有高相似、锚点干净的先例校准tp/sl。
形态:礼来近期多笔BD已属已知背景，早期资产收购可能见光后反应有限，但缺少量化样本。
工具执行结果 · 成功 5 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,248 字
Oil rises 3% as U.S. strikes on Iran revive Hormuz supply disruption concerns
INDIANAPOLIS and CAMBRIDGE, Mass. - Eli Lilly and Company (NYSE:LLY) announced today a definitive agreement to acquire Merida Biosciences, Inc., a biotechnology company developing therapeutics for autoimmune and allergic diseases, for up to $2.875 billion in cash.
The acquisition includes an upfront payment and contingent milestone payments, according to a press release statement. The transaction is subject to customary closing conditions and regulatory approvals, with an expected close in the fourth quarter of 2026.
Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies. The company’s lead program, MER511, is in Phase 1 development for Graves’ disease and thyroid eye disease. Initial Phase 1 data showed MER511 achieved reductions in pathogenic thyroid-stimulating antibodies.
Graves’ disease affects approximately 3 million people in the U.S., and roughly 25 to 40 percent of people with Graves’ disease develop thyroid eye disease. Current approved treatments for both conditions do not directly target the autoantibodies that cause them.
Merida’s pipeline also includes MER769, a preclinical program focused on food allergy, asthma, chronic spontaneous urticaria and other diseases, along with earlier-stage programs in kidney diseases such as membranous nephropathy.
"We’re building our pipeline around therapies that meaningfully change the course of disease, not just its downstream effects," said Francisco Ramírez-Valle, senior vice president of Lilly immunology research and early clinical development.
Adam Townsend, chief executive officer of Merida, said the acquisition "gives our science the resources and commitment to realize its potential for patients with immune-mediated conditions."
Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles upon closing.
Centerview Partners LLC is acting as financial advisor to Merida, with Goodwin Procter LLP serving as legal counsel. Ropes & Gray LLP is acting as legal counsel to Lilly.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
INDIANAPOLIS and CAMBRIDGE, Mass. - Eli Lilly and Company (NYSE:LLY) announced today a definitive agreement to acquire Merida Biosciences, Inc., a biotechnology company developing therapeutics for autoimmune and allergic diseases, for up to $2.875 billion in cash.
The acquisition includes an upfront payment and contingent milestone payments, according to a press release statement. The transaction is subject to customary closing conditions and regulatory approvals, with an expected close in the fourth quarter of 2026.
Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies. The company’s lead program, MER511, is in Phase 1 development for Graves’ disease and thyroid eye disease. Initial Phase 1 data showed MER511 achieved reductions in pathogenic thyroid-stimulating antibodies.
Graves’ disease affects approximately 3 million people in the U.S., and roughly 25 to 40 percent of people with Graves’ disease develop thyroid eye disease. Current approved treatments for both conditions do not directly target the autoantibodies that cause them.
Merida’s pipeline also includes MER769, a preclinical program focused on food allergy, asthma, chronic spontaneous urticaria and other diseases, along with earlier-stage programs in kidney diseases such as membranous nephropathy.
"We’re building our pipeline around therapies that meaningfully change the course of disease, not just its downstream effects," said Francisco Ramírez-Valle, senior vice president of Lilly immunology research and early clinical development.
Adam Townsend, chief executive officer of Merida, said the acquisition "gives our science the resources and commitment to realize its potential for patients with immune-mediated conditions."
Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles upon closing.
Centerview Partners LLC is acting as financial advisor to Merida, with Goodwin Procter LLP serving as legal counsel. Ropes & Gray LLP is acting as legal counsel to Lilly.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。